Revolution Medicines (RVMD) Net Income towards Common Stockholders (2019 - 2026)
Revolution Medicines' quarterly Net Income towards Common Stockholders came in at -$453.8 million in Q1 2026, down 112.64% year-on-year from $3.6 billion in Q1 2025, and down 24.37% quarter-over-quarter from -$364.9 million in Q4 2025.
Revolution Medicines has reported Net Income towards Common Stockholders for 8 years, with the latest figure at -$453.8 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 112.64% year-over-year to -$453.8 million; the trailing twelve-month figure through Mar 2026 stood at -$1.4 billion (down 96.66% YoY), and the FY2025 full-year result was -$1.1 billion, down 88.52% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$453.8 million, down from -$364.9 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$56.5 million in Q4 2022, with the low at -$453.8 million in Q1 2026.
- Average Net Income towards Common Stockholders over 5 years is -$168.8 million, with a median of -$133.2 million recorded in 2024.
- Year-over-year, Net Income towards Common Stockholders slipped 7.31% in 2022 and sank 185.77% in 2023.
- Tracing RVMD's Net Income towards Common Stockholders over 5 years: stood at -$56.5 million in 2022, then slumped by 185.77% to -$161.5 million in 2023, then dropped by 20.45% to -$194.6 million in 2024, then plunged by 87.54% to -$364.9 million in 2025, then slipped by 24.37% to -$453.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$453.8 million (Q1 2026), -$364.9 million (Q4 2025), and -$305.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -453.82 Mn |
| Dec 31, 2025 | -364.89 Mn |
| Sep 30, 2025 | -305.21 Mn |
| Jun 30, 2025 | -247.79 Mn |
| Mar 31, 2025 | -213.42 Mn |
| Dec 31, 2024 | -194.57 Mn |
| Sep 30, 2024 | -156.29 Mn |
| Jun 30, 2024 | -133.23 Mn |
| Mar 31, 2024 | -116.00 Mn |
| Dec 31, 2023 | -161.54 Mn |
| Sep 30, 2023 | -108.43 Mn |
| Jun 30, 2023 | -98.30 Mn |
| Mar 31, 2023 | -68.10 Mn |
| Dec 31, 2022 | -56.53 Mn |
| Sep 30, 2022 | -73.33 Mn |
| Jun 30, 2022 | -61.22 Mn |
| Mar 31, 2022 | -57.65 Mn |
| Dec 31, 2021 | -52.68 Mn |
| Sep 30, 2021 | -52.94 Mn |
| Jun 30, 2021 | -44.30 Mn |
| Mar 31, 2021 | -37.18 Mn |
| Dec 31, 2020 | -34.20 Mn |
| Sep 30, 2020 | -27.22 Mn |
| Jun 30, 2020 | -27.22 Mn |
| Mar 31, 2020 | -21.74 Mn |
| Dec 31, 2019 | -18.85 Mn |
| Sep 30, 2019 | -17.07 Mn |
| Jun 30, 2019 | -13.18 Mn |
| Mar 31, 2019 | -12.81 Mn |